This means that the mechanism by which SLC11A1 influences CL disease may be different to its influence on visceral leishmaniasis in mice following intravenous needle injection [28], or in natural infection of dogs [29,30] and humans [31,32], consistent with its many pleiotropic effects [11]. The gene discussed is SLC11A1; the disease is visceral leishmaniasis.